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Abstract
The tumor microenvironment consists of tumor, immune, stromal, and inflammatory cells which
produce cytokines, growth factors, and adhesion molecules that promote tumor progression and
metastasis. Of particular interest in this setting is interleukin-1 (IL-1), a pleiotropic cytokine with
numerous roles in both physiological and pathological states. It is known to be up regulated in many
tumor types and has been implicated as a factor in tumor progression via the expression of
metastatic and angiogenic genes and growth factors. A number of studies have reported that high
IL-1 concentrations within the tumor microenvironment are associated with a more virulent tumor
phenotype. Solid tumors in which IL-1 has been shown to be up regulated include breast, colon,
lung, head and neck cancers, and melanomas, and patients with IL-1 producing tumors have
generally bad prognoses. The exact mechanisms by which IL-1 promotes tumor growth remain
unclear, though the protein is believed to act via induction of pro-metastatic genes such as matrix
metalloproteinases and through the stimulation of adjacent cells to produce angiogenic proteins
and growth factors such as VEGF, IL-8, IL-6, TNFα, and TGFβ. The IL-1 receptor antagonist (IL-
1ra) is a naturally occurring inhibitor to IL-1 and acts by binding to the IL-1 receptor without
activating it. The protein has been shown to decrease tumor growth, angiogenesis, and metastases
in murine xenograft models. Our focus in this review is to summarize the known data on the role
of IL-1 in tumor progression and metastasis and the use of IL-1 inhibition as a novel therapeutic
approach in the treatment of solid organ malignancies.
Background
The tumor microenvironment consists of tumor,
immune, stromal, and inflammatory cells all of which
produce cytokines, growth factors, and adhesion mole-
cules that may promote tumor progression and metas-
tases. All intimately interact with one another and play an
important role in inflammatory and pro-angiogenic proc-
esses and promote tumor cell proliferation. Interestingly,
there is an association between chronic inflammation and
tumor development or progression; 15% of all cancers are
attributed to inflammatory etiologies [1]. The normal
physiologic inflammatory response occurs upon tissue
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injury due to mechanical stimuli, infectious agents, or
chemical irritation. Inflammatory cells communicate with
fibroblasts and stromal cells via cytokines and chemok-
ines and under the usual circumstances, reparative inflam-
mation is limited. However, chronic pathological
inflammation is mediated via the continuing presence of
a persistent stimulus, such as tumor cells, and the result-
ing prolonged inflammatory cytokine exposure has the
potential to promote tumor growth through the induc-
tion of angiogenesis, DNA damage, and other events favo-
rable to tumor invasion and metastases, as reviewed in
reference [2].
Cytokines regulate growth, trafficking, signalling, and dif-
ferentiation of both stromal and tumor cells. The
cytokines produced by cancer cells function to create opti-
mal growth conditions within the tumor microenviron-
ment, while the cytokines secreted by stromal cells may
influence the behavior of malignant cells [3]. Cytokines
induced by hypoxia, a hallmark feature present in progres-
sive cancers, include vascular endothelial growth factor
(VEGF), tumor necrosis factor (TNF), IL-1, and IL-6, as
reviewed in reference [2]. TNF is a mediator of acute and
chronic inflammation and has been detected in colon,
breast, prostate and ovarian carcinomas as well as lym-
phomas and leukemias [4]. TNF, IL-6, and IL-8 can
directly or indirectly promote tumor growth via induction
of VEGF expression [5,6]. Of particular interest is IL-1, a
pleiotropic cytokine with numerous roles in both physio-
logical and pathological states. It is known to be up regu-
lated in many tumor types and has been implicated as a
factor in tumor progression via the expression of meta-
static and angiogenic genes and growth factors. A number
of studies have reported that high IL-1 concentrations
within the tumor microenvironment are associated with a
more virulent tumor phenotype. The exact mechanism
through which IL-1 exerts its proliferative and angiogenic
effects is unknown; it is postulated that interactions
within the tumor microenvironment are believed an
important component.
IL-1 receptor antagonist (IL-1ra) is an approved treatment
for patients with rheumatoid arthritis and is being inves-
tigated as a potential novel therapeutic in cancer treat-
ment. This naturally occurring protein has been shown to
decrease tumor growth, angiogenesis, and metastases in
murine xenograft models. There are other agents that are
capable of inhibiting the inflammatory and tumor pro-
moting effects of IL-1 such as anti-interleukin-1 mono-
clonal antibodies, the soluble IL-1 receptor type II,
interleukin-1β-converting enzyme inhibitors, and IL-1
cytokine traps. Such potential therapeutic agents are cur-
rently being applied to the treatment of rheumatoid
arthritis, but additional studies are necessary to determine
their ability as novel therapy in cancer treatment. Our
focus here is on the metastatic and angiogenic properties
of IL-1 and the inhibition of this pro-inflammatory
cytokine as a novel therapeutic approach in the treatment
of solid organ malignancies.
Biochemistry of IL-1
Three proteins comprise the IL-1 family, two of which are
agonists, IL-1α and IL-1β; the third is IL-1 receptor antag-
onist (IL-1ra). IL-1α and IL-1β are derived from different
genes but are functionally similar, and both bind to the
same receptor [7-9]. Although they exhibit similar biolog-
ical activities, IL-1α and IL-1β differ in the manner in
which they are processed and secreted. IL-1α is localized
in the cytosol or cell membrane and is believed to regulate
the intracellular environment [8,9]. In contrast, IL-1β is
first cleaved by interleukin-1β-converting enzyme (ICE)
to its mature active form and then secreted extracellularly.
Patients with infectious or inflammatory conditions
exhibited elevated plasma concentrations of IL-1β but not
IL-1α, suggesting the systemic role of IL-1β [9,10].
There are two IL-1 receptors, the biologically active IL-1
receptor type I (IL-1RI) and the IL-1 receptor type II (IL-
1RII). Both are members of the immunoglobulin super-
family and contain structurally similar IL-1 binding sites
[8]. IL-1RI is expressed on most cell types, preferentially
binds IL-1α, and is responsible for the signal transduction
of IL-1, whereas IL-1RII acts as an antagonist. Found
within B lymphocytes, neutrophils, and monocytes, IL-
1RII preferentially binds IL-1β and contains a shorter
cytoplasmic segment. This decreases its signal transduc-
tion ability, attenuating the response to IL-1. Due to these
antagonistic effects, IL-1RII is referred to as a decoy IL-1
receptor, resulting in its potential as a novel therapeutic
agent [8,11]. Upon binding of IL-1 to either receptor type,
the IL-1R accessory protein (IL-1RAcP) is recruited to the
complex [11]. The IL-1RAcP facilitates signal transduction
via the recruitment of kinases and activator and intracellu-
lar proteins. Without IL-1RAcP, IL-1 remains capable of
binding IL-1RI but signal transduction is unable to occur
[11,12]. This important mechanism affects the efficacy of
therapeutics such as IL-1ra that attempt to prevent the IL-
1 and IL-1RI interaction.
IL-1 in cancer
IL-1 is a pluripotent cytokine responsible for normal
physiological roles ranging from the induction of vascular
permeability and fever during sepsis to the increased
secretion of additional cytokines in autoimmune diseases.
Other roles of IL-1 include production and release of pros-
taglandins, pituitary hormones, and collagenases. IL-1
also stimulates the immune system to boost production
of lymphocytes. Therefore, an important balance exists
between the beneficial and harmful effects of IL-1. It can
negatively impact the vascular, endocrine, connective tis-Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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sue, immune, haematopoietic, and central nervous sys-
tems, rendering it an important therapeutic target in a
number of pathological conditions including rheumatoid
arthritis, atherosclerosis, diabetes mellitus type I, inflam-
matory bowel disease and other autoimmune disorders,
Alzheimer's disease, leukaemia, and solid tumors
[8,13,9].
Cancer cells directly produce IL-1 or can induce cells
within the tumor microenvironment to do so [14]; studies
have documented constitutive IL-1β protein production
in human and animal cancer cell lines including sarcomas
and ovarian and transitional cell carcinomas [9]. Solid
tumors in which IL-1β has been shown to be up regulated
include breast, colon, lung, head and neck cancers, and
melanomas, and patients with IL-1β producing tumors
have generally bad prognoses [6,15-17]. Elaraj et al [15]
evaluated melanoma, non-small cell carcinoma, colon,
and squamous cell cancer cell lines for the gene expression
of IL-1α and IL-1β via real time quantitative reverse tran-
scriptase PCR and found several of these lines to exhibit
significantly increased copy numbers of IL-1α or IL-1β
(Table 1). The expression patterns of IL-1 vary; it is
expressed in an autocrine or paracrine fashion [18]. IL-1
exhibits autocrine behavior by stimulating the tumor cell
itself to invade and proliferate, or it can exert paracrine
effects on stromal cells in the microenvironment. The
exact mechanisms by which IL-1 promotes tumor growth
remain unclear, though the protein is believed to act pri-
marily indirectly (Figure 1). IL-1 induces expression of
metastatic genes such as matrix metalloproteinases
(MMP) and stimulates nearby cells to produce angiogenic
proteins and growth factors such as VEGF, IL-8, IL-6,
TNFα, and tumor growth factor beta (TGFβ) [9,19-21].
Recent studies have determined the necessity of IL-1 in
tumor growth, metastasis, and angiogenesis [7,9].
Tumor growth and metastases
The ability of IL-1 to induce the expression of angiogenic
factors such as VEGF and IL-8 is believed to promote
tumor growth and metastasis. Tumor metastasis is a
multi-step process requiring numerous factors such as
interactions between the tumor cell and its microenviron-
ment [7,19,22]. Sawai et al [22] evaluated the role of IL-1
in metastatic and non-metastatic pancreatic cancer cell
lines. Metastatic lines demonstrated increased IL-1RI
expression compared to non-metastatic lines and expo-
sure to IL-1α resulted in increased α6- and β1- integrin
subunit expression, whereas IL-1α exposure in non-meta-
static lines had no effect [22]. Additionally, IL-1α induced
adhesion and invasion into laminin in metastatic pancre-
atic cell lines but not in non-metastatic lines. These stud-
ies highlighted the importance of IL-1α in cell adhesion
and invasion into extracellular matrix proteins, and stud-
ies by Voronov et al [7] complement findings regarding
the importance of IL-1 in metastasis. They demonstrated
that IL-1α/IL-1β knockout mice failed to develop solid
tumors following injection of melanoma cells and exhib-
ited significantly improved survival compared to the wild-
type animals, which died due to lung metastases [7]. Addi-
tional findings established that IL-1β was predominately
responsible for the increased metastatic potential of the
tumors. These studies indicate that presence of the IL-1RI
receptor in cancer cells and IL-1 in the tumor microenvi-
ronment are important factors in tumor cell angiogenesis
and adhesion and invasion into extracellular matrix
[7,22].
Angiogenesis
The ability of IL-1 to promote tumor proliferation and
metastases is mediated via neovascularization [7,9,15];
studies suggest the angiogenic effects of IL-1 are indirect
[7,23]. The indirect effects of IL-1 were illustrated in
mouse Lewis lung carcinoma cells by Saijo et al [24]. Cells
transduced with IL-1β showed no difference in prolifera-
tion rates in vitro but exhibited significantly increased
tumor growth rates when injected into mice [24]. Addi-
tionally, there were increased microvessels and immuno-
histochemical staining against the endothelial cell
marker, CD31, in transduced xenografts compared with
the wild-type and null transfected xenografts. To further
elucidate the angiogenic role of IL-1, the study measured
concentrations of VEGF, macrophage-inflammatory pro-
tein-2 (MIP-2, the mouse homolog to human IL-8), and
hepatocyte growth factor (HGF) proteins secreted by IL-
1β-transduced Lewis lung carcinoma cells in vitro. In vitro
production of VEGF and MIP-2 was significantly
increased, but HGF was increased only in IL-1β-trans-
duced xenografts. Such results demonstrate both the
importance of the interaction between IL-1 and the tumor
microenvironment and the indirect effects of IL-1 [24].
Previous studies in our laboratory [15] further demon-
strate the indirect angiogenic properties of IL-1. The super-
natant from two melanoma cell lines (PMEL and SMEL)
with differential IL-1 expression (low versus high, respec-
tively) was used in an in vitro endothelial cell permeability
assay and results demonstrated that only IL-1 producing
cell lines (SMEL and non-small-cell carcinoma, H2030)
exhibited increased permeability that was inhibited by IL-
1ra. Increased absorbance indicates increased endothelial
cell permeability, an early step in angiogenesis (Figure 2)
[15].
A study by Voronov et al [7] demonstrated that IL-1 is
essential for angiogenesis and tumor proliferation. They
found significantly increased staining for anti-Von Wille-
brand factor in melanoma cell-containing Matrigel plugs
implanted into wild-type mice compared with IL-1β KO
mice. Additionally, the angiogenic effects of IL-1 observed
in the wild-type model were restored when IL-1β KO miceJournal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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received plug implants containing melanoma cells with
IL-1α. These studies found that IL-1 produced within the
microenvironment and endogenously produced IL-1 are
necessary in the neovascularization of tumors [7].
Anti-tumor activities of IL-1ra
IL-1ra, the third member of the IL-1 family, is a naturally
occurring protein that competitively blocks the IL-1RI on
T lymphocytes and fibroblasts [8]. Due to its ability to
block collagenase and prostaglandin synthesis within
chondrocytes and synovial cells, IL-1ra (anakinra) is
approved for the treatment of rheumatoid arthritis and
has been showed as useful in the reversal of IL-1 mediated
effects in several pathological settings [8]. IL-1ra pre-
vented severe and lethal hypotension in rabbits adminis-
tered LPS [25] and attenuated IL-1 mediated intestinal
inflammation and necrosis in the immune complex-
induced colitis animal model [26]. Additionally, IL-1ra
blocked IL-1 induced production of colony-stimulating
growth factors (CSF) by fibroblasts, lymphocytes, and
monocytes in acute and chronic myelogenous leukemias
[27]. Anakinra is well absorbed in humans, and its safety
is well documented with few adverse reactions, making it
an ideal candidate in the adjuvant therapy in cancers.
Proposed model of how IL-1 indirectly alters tumor growth and metastatic potential in vivo Figure 1
Proposed model of how IL-1 indirectly alters tumor growth and metastatic potential in vivo. In the tumor micro-
environment IL-1 has local effects on host infiltrating cells that result in production of proangiogenic and prometastatic media-
tors.
Table 1: Results of IL-1α or IL-1β mRNA expression in several tumor cell lines evaluated by quantitative RT-PCR.
Human tumor cell lines IL-1α*I L - 1 β*
SMEL (melanoma) 3,267 0
WIDR (colon cancer) 1 122,932
H2030 (NSCLC) 0 29,084
PMEL (melanoma) 35 67
SL-2 (squamous cell cancer) 140 0
* Gene expression is expressed as copy number per 105 copies of β-actin; copy number > 1,000/105 copies β-actin is in boldface.Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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Induction of endothelial cell monolayer permeability by tumor conditioned supernatant in an IL-1-dependent manner Figure 2
Induction of endothelial cell monolayer permeability by tumor conditioned supernatant in an IL-1-dependent 
manner. Permeability across functional endothelial cell monolayers was determined by measuring absorbance at 620 nm 1 
hour following supernatant exposure. Induction of permeability by SMEL (A) and H2030, a lung non-small-cell carcinoma, (B) 
was completely or partially blocked by co incubation with 10 mg/mL IL-1Ra. PMEL did not induce permeability under identical 
experimental conditions (C). Tumor necrosis factor (TNF) at 10 ng/mL served as positive control. Columns, mean; bars, SE.Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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Because IL-1 promotes angiogenesis, tumor growth, and
metastases, numerous studies have examined the mecha-
nism and ability of IL-1ra to block such effects. One such
study by Konishi et al [19] found that IL-1ra inhibited
both in vitro and in vivo Vascular Endothelial Growth Fac-
tor production in colon adenocarcinoma cell lines and
tumors. They noted an IL-1β dose dependent production
of VEGF protein and mRNA expression in cultured colon
cancer cell lines. Secretion of the protein was significantly
suppressed when the cells were pretreated with IL-1ra.
VEGF, IL-1β, and IL-1ra concentrations were quantified in
tumor samples from patients with colon cancer, and a cor-
relation was observed between the VEGF protein and the
IL-1ra: IL-1β ratio within the tumor. Lower ratios of IL-
1ra:IL-1β within the tumor correlated with increased con-
centrations of VEGF protein [19].
Our recent studies focused on the effects of constitutively
produced IL-1ra on human melanoma xenografts in a
murine model [28]. The specific effects of IL-1ra on tumor
proliferation and metastases via the transduction of
human IL-1ra into two human melanoma cell lines
(PMEL and SMEL) with differential IL-1β expression (low
vs. high, respectively) were illustrated. IL-1ra-transduced,
null-transduced, and wild-type cells were grown in vitro.
There were no differences in growth rates among the three
groups, indicating the lack of direct autocrine effects of IL-
1ra on tumor growth. Similarly, ELISA assays confirmed
that IL-1ra did not alter the secretion of IL-1β in trans-
duced cells versus the wild-type. IL-1ra behaved in a para-
crine fashion, as illustrated by a mixing study in which
wild-type SMEL melanoma cells and SMEL lines trans-
duced with IL-1ra (SMEL/IL-1ra) were mixed in varying
ratios ex vivo and then injected into athymic mice. All
tested SMEL:SMEL/IL-1ra ratios resulted in significantly
decreased tumor cross-sectional areas, thus demonstrating
the paracrine effects of constitutively produced IL-1ra
(Figure 3) [28].
The importance of the presence of IL-1 as a tumor growth
factor in vivo was also examined. IL-1ra-transduced and
wild-type SMEL and PMEL cells were injected subcutane-
ously into nude mice, and only tumors which constitu-
tively produced IL-1β (SMEL) were affected by IL-1ra
transduction. There was significantly decreased tumor
growth between the SMEL/IL-1ra and the null-transduced
and wild-types, whereas there was no difference in the low
IL-1β secreting line [28]. Additionally, SMEL/IL-1ra
tumors exhibited massive necrosis within the center of the
tumor which was not present in wild-type tumors, and
pulmonary metastases in the SMEL/IL-1ra group were sig-
nificantly fewer than in the null-transduced and wild-type
groups (Figure 4) [28].
Another study evaluated the mechanism and effects of sys-
temically administered IL-1ra on established human
tumors in a murine model. Human cancer xenografts in
mice receiving systemic IL-1ra administration showed
decreased tumor growth and metastases only when the
tumor secreted significant concentrations of IL-1β. Histo-
logically, we failed to note any significant differences in
mitotic rate between control and IL-1ra treated tumors
obtained from mice. This coupled with in vitro experi-
ments that also failed to demonstrate alteration in prolif-
eration rates between IL-1ra treated and control cells,
emphasizes the indirect role of IL-1 and the importance of
its interaction between the tumor and microenvironment.
This indirect role was further examined in experiments
investigating the effect of IL-1ra on gene expression of IL-
8. Iinterleukin-8, an angiogenic cytokine induced by IL-1,
acts on endothelial cells to promote chemotaxis, cell
retraction, and gap formation [8,29]. The results demon-
strated that although IL-1ra treatment decreased IL-8
mRNA expression and protein concentration in IL-1ra
sensitive xenografts, it had no effect in vitro [15]. There-
fore, it is likely that the mechanism by which IL-1ra exerts
its effects is through the tumor microenvironment rather
than through direct blockade of the IL-1RI [15].
Multiple studies have investigated the necessity of IL-1 in
tumor growth, metastases, and angiogenesis, which has
resulted in the investigation of IL-1ra as a novel therapeu-
tic agent in solid tumors constitutively producing IL-1.
Such studies have found that IL-1ra decreases metastases
and tumor proliferation in vivo, as well as decreasing the
gene expression and production of angiogenic proteins
such as VEGF and IL-8. A summary of the demonstrated
anti-tumor activities of IL-1 blocking therapies is reviewed
in Table 2. Based on these data, IL-1ra may prove clinically
relevant in the treatment of certain cancers when used
either alone or in conjunction with other chemotherapeu-
tics.
Novel therapeutic anti-IL-1 agents
Despite numerous studies citing the safety and potential
beneficiary effects of IL-1ra, there exist questions regard-
ing its efficiency in long term treatment of diseases such as
cancer. Although anakinra has proven successful in the
treatment of rheumatoid arthritis in select patients, large
doses are required daily to elicit responses. IL-1 receptors
are regenerated rapidly and with the exception of red
blood cells, are ubiquitously expressed throughout the
body. This, combined with IL-1ra's short half-life (4–6 h)
presents formidable challenges to the therapeutic poten-
tial of this compound in cancer treatment. For IL-1ra to
completely neutralize the tumor proliferating, angiogenic,
and metastatic effects of IL-1, sustained concentrations are
necessary to saturate all IL-1 receptors. Recent studies
[15,28] support this hypothesis. In mice treated with IL-Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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1ra, only partial xenograft inhibition was observed,
whereas IL-1ra-transduced xenografts demonstrated near
complete growth inhibition (Figures 3 &5) [15,28]. Thus,
although IL-1ra has demonstrated some benefit as a can-
cer therapeutic, many other novel therapies remain under
investigation.
Anti-interleukin-1 monoclonal antibodies
Therapies using antibodies to IL-1β have been investi-
gated by Neidhart et al. IL-1ra and anit-IL-1β monoclonal
antibodies tested individually on a human rheumatoid
arthritis cartilaginous matrix model decreased cartilagi-
nous destruction by 45% and 35%, respectively [30].
Additionally, CDP-484 (Celltech), a pegylated IL-1β anti-
body, has demonstrated inhibitory IL-1β activities as
measured by decreased neutrophil accumulation, as
reviewed by Braddock et al [31]. In their review, Braddock
et al report an in vivo study in which mice with collagen-
induced arthritis were either treated with prophylactic
pegylated IL-1β antibody or vehicle. Only 20% of mem-
bers of the prophylactic group developed collagen-
induced arthritis, whereas 90% of the control group devel-
oped the disease [31].
Soluble IL-1RII
As mentioned previously, the IL-1 type II receptor (IL-
1RII) behaves as a decoy receptor due to its lack of the
cytoplasmic domain necessary for signal transduction. It
therefore behaves as an inhibitor of IL-1 activity. IL-1RII
occurs in membrane bound and soluble forms; the solu-
Anti-tumor activity of IL-1ra gene transduction and over-expression in melanoma xenografts Figure 3
Anti-tumor activity of IL-1ra gene transduction and over-expression in melanoma xenografts. An IL-1 producing 
melanoma (SMEL) was mixed at the indicated ratios with the same cell line that was transduced to over-express IL-1ra (SMEL/
IL-1ra) ex vivo and injected s.c. into athymic nude mice. There was significant growth inhibition at all tested ratios, indicating a 
marked paracrine effect of IL-1ra on tumor growth.Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
Page 8 of 12
(page number not for citation purposes)
ble IL-1RII (sIL-1RII) form naturally occurs in the synovial
fluid and plasma of healthy human subjects [32,33]. A
negative correlation between sIL-1RII protein concentra-
tions and presence of chronic arthritis in patients was
noted by Jouvenne et al in which decreased sIL-1RII pro-
tein concentrations were observed in patients with
chronic arthritis [34]. These data implicate the potential
anti-inflammatory effects of the soluble type II receptor.
Other studies provided further evidence of the inhibitory
role of sIL-1RII in the signaling and transduction of IL-1.
Table 2: Established anti-tumor activities of IL-1 blocking methods and/or therapies based on published literature.
Study Year Observation
Voronov et al [7] 2003 IL-1 KO mice failed to develop solid tumors post injection of melanoma cells and exhibited significantly improved 
survival compared with wild type animals.
Saijo et al [19] 2002 Overexpression of IL-1 is associated with an aggressive/malignant phenotype.
Sawai et al [22] 2003 Same observation as above
Voronov et al [7] 2003 Same observation as above
Weinreich et al [28] 2003 IL-1ra-transduced xenografts exhibited decreased tumor growth and metastases in murine models.
Elaraj et al [15] 2006 Exogenously administered IL-1ra (anakinra) decreased tumor proliferation rate, metastases, and IL-8 and VEGF 
mRNA expression of xenografts in murine models.
Inhibition of lung metastases in IL-1ra over-expressing melanoma xenografts Figure 4
Inhibition of lung metastases in IL-1ra over-expressing melanoma xenografts. There was marked inhibition of lung 
metastases from the SMEL/IL-1ra cells compared with the null-transduced and wild-type controls. Cells were injected via tail 
vein, and the lungs were harvested 28 days later.Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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Both in vitro and in vivo studies demonstrated that IL-1RII-
transduced cells failed to respond to IL-1 [35,36]. Bessis et
al used a collagen-induced arthritis murine model synon-
ymous to human inflammatory arthritis to demonstrate
the anti-inflammatory properties of sIL-1RtII. Human sIL-
1RII-transfected keratinocytes engrated into arthritic mice
decreased clinical and histological arthritis characteristics
and decreased IL-6 and myeloperoixdase mRNA expres-
sion within the joints [37].
Although the IL-1RII is not responsible for IL-1 signal
transduction, it does recruit the IL-1R accessory protein
(IL-1RAcP) upon binding to IL-1. As previously discussed,
IL-1RAcP is a necessary component for signal transduc-
tion of IL-1. The IL-1 neutralizing effects of sIL-1RII then,
are twofold; it sequesters IL-1RAcP, preventing its interac-
tion with the IL-1RI and IL-1 complex, and it acts as a
decoy by binding IL-1 and preventing its binding to the
signal transducing IL-1RI [12,38]. These complementary
inhibitory mechanisms enhance the IL-1 blocking effects
of sIL-1RII. Additionally, sIL-1RII has increased the IL-1
blocking effects of IL-1ra, and studies cite evidence that
sIL-1RII and IL-1ra interact synergistically to block IL-1
activity [39,40]. Burger et al found that sIL-1RII and IL-1ra
administered simultaneously to human keratinocytes in
vitro resulted in decreased production of prostaglandin E2
and metalloproteinases compared with either one treat-
ment alone [40]. Based on such studies, combined novel
Partial tumor growth inhibition in IL-1 but not non-IL-1 producing xenografts treated with systemic IL-1ra protein Figure 5
Partial tumor growth inhibition in IL-1 but not non-IL-1 producing xenografts treated with systemic IL-1ra 
protein. Two times 106 tumor cells were injected s.c. into the flanks of athymic nude mice. On the day of tumor injection, s.c. 
IL-1ra therapy at various doses or placebo began and was administered daily into the opposite flank from tumor injection. IL-
1ra consistently resulted in a statistically significant decrease in growth rate of all three IL-1-producing tumors tested but had 
no effect on two non-IL-1-producing tumors.Journal of Translational Medicine 2006, 4:48 http://www.translational-medicine.com/content/4/1/48
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therapeutics may be more effective in blocking the delete-
rious effects of IL-1 than individual treatments.
Interleukin-1β-converting enzyme (ICE) inhibitors
IL-1β-converting enzyme (ICE), also known as caspase-1,
is a protease necessary in the conversion of inactive IL-1β
to the mature pro-inflammatory form and recently has
been investigated as a novel therapeutic agent with IL-1β
blocking potential. Additionally, ICE is responsible for
the conversion of the pro-IL-18 form to its mature active
form. Thus the advantages of employing ICE inhibitors
are twofold: they diminish the actions of inflammatory
cytokines IL-1 and IL-18 [41]. Due to the oral availability
of ICE inhibitors, they are advantageous compared with
injectable protein products such as IL-1ra. Patients prefer
oral medications over injected ones, and orally adminis-
tered drugs may result in better compliance and reduced
cost [42]. The safety of ICE inhibitors remains under sur-
veillance, and animal studies suggest this therapeutic is
well-tolerated. Such studies found that genetically ICE-
deficient mice did not appear to be at increased risk of
developing infection or malignancies [43,44]. Further-
more, Rudolphi et al report that pralnacasan, the first
orally bioavailable ICE inhibitor tested in humans, was
well-tolerated in healthy subjects in a phase I/IIa clinical
trial [45]. The effectiveness of pralnacasan was also inves-
tigated by Rudolphi et al in two osteoarthritis murine
models where pralnacasan significantly decreased his-
topathological joint cartilage destruction. A phase II clini-
cal trial involving pralnacasan for the management of
osteoarthritis is underway [45]. ICE inhibiting agents such
as pralnacasan and the more recent VX-765 demonstrate
promise as anti-inflammatory therapeutics in that they are
orally available and they elicit the anti-inflammatory
response via the inhibition of the activities of both IL-1
and IL-18.
Cytokine traps
As discussed previously, IL-1 first binds to the IL-1RI, then
recruits a second binding protein, the IL-1RAcP. IL-1
binds more avidly to this complex than the individual
receptor, which is the basis upon which cytokine traps
were founded [46]. Cytokine traps are produced by
eukaryotic cells in culture and are soluble recombinant
proteins consisting of cytokine cell-surface receptor
domains bound inline to the Fc portion of human IgG1.
These dimeric molecules avidly bind the cytokine of inter-
est and have been developed for TNFα, IL-4, IL-6, and IL-
1 [46]. Both in vitro and in vivo studies by Economides et
al determined that the IL-1 trap more effectively blocked
IL-1 and its effects than did IL-1ra. In vitro experiments
measured the relative efficacies (IC50) of the IL-trap and
IL-1ra; in the presence of IL-1β (4 pM), the IC50 of IL-1
trap versus IL-1ra were 2 pM and 70 pM, respectively [46].
Additionally, the IL-1 trap avidly bound to IL-1α as well
as IL-1β, an advantage over monoclonal antibodies
against a single form of IL-1. In vivo studies found that IL-
1 traps injected subcutaneously into mice 24 h prior to
injection with IL-1β resulted in complete inhibition of IL-
6 production, a cytokine induced by IL-1. This single dose
also blocked the effects of a subsequent IL-1β injection 24
hours later, thus highlighting the ability of the IL-1 trap to
exert its blocking activities over a prolonged amount of
time. In contrast, IL-1ra did not inhibit the activities of IL-
1 when administered at a dose 15-fold greater than the IL-
1 trap dose [46].
To date, this study has demonstrated that the IL-1 trap has
more successfully inhibited IL-1 activity than any other
published study involving IL-1 blocking therapies, and
based on entropy principles, it has been suggested that the
IL-1 trap may bind IL-1 more avidly than even the IL-1RI
itself [46]. Additionally, the ability of IL-1 traps to bind
multiple cytokines such as IL-1α and IL-1β, coupled with
its prolonged half life in vivo render it a rapidly emerging
novel therapeutic agent in the inhibition of IL-1 activity.
Results of a completed phase II study involving the treat-
ment of 200 patients with weekly subcutaneous doses of
IL-1 trap have been reported [31]. In this clinical trial, IL-
1 traps appeared to be safe, well-tolerated, and elicited no
abnormal clinical laboratory values or evidence of
increased number of infections, thus supporting further
investigations of this protein.
Conclusion
Elevated IL-1 concentrations have been identified in
numerous types of solid tumors in which the prognoses is
markedly worse. This pleiotropic cytokine promotes
tumor proliferation, angiogenesis, and metastases via its
autocrine and paracrine effects within the tumor itself as
well as the microenvironment. Our recent studies high-
light the potential beneficial effects of both constitutively
produced and exogenously administered IL-1ra, while
numerous other IL-1 blocking therapeutics including anti-
IL-1 monoclonal antibodies, soluble IL-1RII, ICE inhibi-
tors, and IL-1 cytokine traps have shown promise in the
treatment of rheumatoid arthritis. The goal is to apply
such novel treatments either alone or in conjunction with
more traditional approaches towards the inhibition of IL-
1 in the treatment of cancer.
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